These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11313969)

  • 21. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
    Bonicalzi ME; Groulx I; de Paulsen N ; Lee S
    J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIF activation by pH-dependent nucleolar sequestration of VHL.
    Mekhail K; Gunaratnam L; Bonicalzi ME; Lee S
    Nat Cell Biol; 2004 Jul; 6(7):642-7. PubMed ID: 15181450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular cloning and characterization of the von Hippel-Lindau-like protein.
    Qi H; Gervais ML; Li W; DeCaprio JA; Challis JR; Ohh M
    Mol Cancer Res; 2004 Jan; 2(1):43-52. PubMed ID: 14757845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.
    Pugh CW; Ratcliffe PJ
    Semin Cancer Biol; 2003 Feb; 13(1):83-9. PubMed ID: 12507560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
    Mole DR; Maxwell PH; Pugh CW; Ratcliffe PJ
    IUBMB Life; 2001 Jul; 52(1-2):43-7. PubMed ID: 11795592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors.
    Cai QL; Knight JS; Verma SC; Zald P; Robertson ES
    PLoS Pathog; 2006 Oct; 2(10):e116. PubMed ID: 17069461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 stabilization and transactivation by a von Hippel-Lindau protein.
    Roe JS; Kim H; Lee SM; Kim ST; Cho EJ; Youn HD
    Mol Cell; 2006 May; 22(3):395-405. PubMed ID: 16678111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth.
    Mack FA; Rathmell WK; Arsham AM; Gnarra J; Keith B; Simon MC
    Cancer Cell; 2003 Jan; 3(1):75-88. PubMed ID: 12559177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.
    Ohh M; Park CW; Ivan M; Hoffman MA; Kim TY; Huang LE; Pavletich N; Chau V; Kaelin WG
    Nat Cell Biol; 2000 Jul; 2(7):423-7. PubMed ID: 10878807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
    Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
    Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma.
    Chan CC; Lee YS; Zhuang Z; Hackett J; Chew EY
    Trans Am Ophthalmol Soc; 2004; 102():75-9; discussion 79-81. PubMed ID: 15747747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. von Hippel-Lindau tumor suppressor: not only HIF's executioner.
    Czyzyk-Krzeska MF; Meller J
    Trends Mol Med; 2004 Apr; 10(4):146-9. PubMed ID: 15162797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of hypoxia-induced transcription in normoxia.
    Hägg M; Wennström S
    Exp Cell Res; 2005 May; 306(1):180-91. PubMed ID: 15878343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIF-1alpha and p53 as targets of NO in affecting cell proliferation, death and adaptation.
    Zhou J; Schmid T; Brüne B
    Curr Mol Med; 2004 Nov; 4(7):741-51. PubMed ID: 15579021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis.
    Jones MK; Szabó IL; Kawanaka H; Husain SS; Tarnawski AS
    FASEB J; 2002 Feb; 16(2):264-6. PubMed ID: 11772947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function.
    Palayoor ST; Burgos MA; Shoaibi A; Tofilon PJ; Coleman CN
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4158-64. PubMed ID: 15217953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.
    Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L
    Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion.
    Demidenko ZN; Rapisarda A; Garayoa M; Giannakakou P; Melillo G; Blagosklonny MV
    Oncogene; 2005 Jul; 24(30):4829-38. PubMed ID: 15897903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.